Standard
Drug screening and molecular profiling identifies INKA1 as a predictive biomarker for sensitivity to MAPK inhibition-antimitotic combination treatment in pancreatic ductal adenocarcinoma. / Gautam, Prson; Vaha-Koskela, Markus; Tomlinson, Max; Cox, Adrienne D.; Der, Channing J.; Aittokallio, Tero; Wennerberg, Krister.
I:
Molecular Cancer Therapeutics, Bind 18, Nr. 12, A137, 2019.
Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › fagfællebedømt
Harvard
Gautam, P, Vaha-Koskela, M, Tomlinson, M, Cox, AD, Der, CJ, Aittokallio, T
& Wennerberg, K 2019, '
Drug screening and molecular profiling identifies INKA1 as a predictive biomarker for sensitivity to MAPK inhibition-antimitotic combination treatment in pancreatic ductal adenocarcinoma',
Molecular Cancer Therapeutics, bind 18, nr. 12, A137.
https://doi.org/10.1158/1535-7163.TARG-19-A137APA
Gautam, P., Vaha-Koskela, M., Tomlinson, M., Cox, A. D., Der, C. J., Aittokallio, T.
, & Wennerberg, K. (2019).
Drug screening and molecular profiling identifies INKA1 as a predictive biomarker for sensitivity to MAPK inhibition-antimitotic combination treatment in pancreatic ductal adenocarcinoma.
Molecular Cancer Therapeutics,
18(12), [A137].
https://doi.org/10.1158/1535-7163.TARG-19-A137Vancouver
Gautam P, Vaha-Koskela M, Tomlinson M, Cox AD, Der CJ, Aittokallio T o.a.
Drug screening and molecular profiling identifies INKA1 as a predictive biomarker for sensitivity to MAPK inhibition-antimitotic combination treatment in pancreatic ductal adenocarcinoma.
Molecular Cancer Therapeutics. 2019;18(12). A137.
https://doi.org/10.1158/1535-7163.TARG-19-A137Author
Gautam, Prson ; Vaha-Koskela, Markus ; Tomlinson, Max ; Cox, Adrienne D. ; Der, Channing J. ; Aittokallio, Tero ; Wennerberg, Krister. / Drug screening and molecular profiling identifies INKA1 as a predictive biomarker for sensitivity to MAPK inhibition-antimitotic combination treatment in pancreatic ductal adenocarcinoma. I: Molecular Cancer Therapeutics. 2019 ; Bind 18, Nr. 12.
Bibtex
@article{332aa0aae88b4aacbc2c6feed72eb1ca,
title = "Drug screening and molecular profiling identifies INKA1 as a predictive biomarker for sensitivity to MAPK inhibition-antimitotic combination treatment in pancreatic ductal adenocarcinoma",
author = "Prson Gautam and Markus Vaha-Koskela and Max Tomlinson and Cox, {Adrienne D.} and Der, {Channing J.} and Tero Aittokallio and Krister Wennerberg",
year = "2019",
doi = "10.1158/1535-7163.TARG-19-A137",
language = "English",
volume = "18",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research (A A C R)",
number = "12",
}
RIS
TY - ABST
T1 - Drug screening and molecular profiling identifies INKA1 as a predictive biomarker for sensitivity to MAPK inhibition-antimitotic combination treatment in pancreatic ductal adenocarcinoma
AU - Gautam, Prson
AU - Vaha-Koskela, Markus
AU - Tomlinson, Max
AU - Cox, Adrienne D.
AU - Der, Channing J.
AU - Aittokallio, Tero
AU - Wennerberg, Krister
PY - 2019
Y1 - 2019
U2 - 10.1158/1535-7163.TARG-19-A137
DO - 10.1158/1535-7163.TARG-19-A137
M3 - Conference abstract in journal
VL - 18
JO - Molecular Cancer Therapeutics
JF - Molecular Cancer Therapeutics
SN - 1535-7163
IS - 12
M1 - A137
ER -
